BioLineRX Ltd (NASDAQ:BLRX) is currently focused on the development of BL-8040, which is a short peptide antagonist for CXCR4, a chemokine receptor involved with tumor progression, angiogenesis, metastasis and cell survival. BL-8040 is being developed for a variety of solid tumors including pancreatic, gastric and NSCLC. It is also being developed for AML and stem cell mobilization. They are also developing AGI-134, an alpha-gal immunotherapy for solid tumors, which is expected to enter the clinic within 12 months. BioLineRx has multiple collaborators including Genentech, Merck (NYSE:MRK) and Novartis (NYSE:NVS).
Getting closer to registration in stem cell mobilization
BioLineRx is set to initiate a registrational study of BL-8040 in autologous stem cell mobilization in H217 following a recent successful meeting with the FDA. A Phase II in their allogeneic transplantation study is expected to have topline results by the end of 2017. The company reported positive early results from this trial in March where BL-8040 showed a similar level of efficacy with a single injection that G-CSF, the current standard of care, shows after four to six injections.
Multiple trials with quality collaborators
Genentech is set to initiate three Phase Ib trials of BL-8040 in combination with atezolizumab in pancreatic, gastric and non-small cell lung cancer (NSCLC). BioLineRx has initiated a Phase II trial of BL-8040 in combination with Keytruda in pancreatic cancer in collaboration with Merck. We expect partial results from this trial in H217 with topline results in H218. The company also has a multi-year collaboration with Novartis to develop early stage molecules. As part of this, Novartis took an equity stake in BioLineRx which currently stands at around 6%.
To read the entire report Please click on the pdf File Below